Navidea Biopharmaceuticals Inc Net debt/EBITDA
Mi az Navidea Biopharmaceuticals Inc Net debt/EBITDA?
A Net debt/EBITDA az Navidea Biopharmaceuticals Inc - 0.38
Mi a Net debt/EBITDA meghatározása?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA a Health Care szektor a NYSEMKT-on cégekben a Navidea Biopharmaceuticals Inc -hoz képest
Mit csinál Navidea Biopharmaceuticals Inc?
navidea biopharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. it operates through two segments, diagnostic substances and therapeutic development programs. the company develops manocept platform to target the cd206 mannose receptor expressed on activated macrophages. its cd206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (pet), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. further, the company offers nav4694, a fluorine-18 labeled pet imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of alzheimer's disease and mild cognitive impairment. in addition, it is de
net debt/ebitda -hoz hasonló cégek Navidea Biopharmaceuticals Inc
- Kühne + Nagel International AG nak Net debt/EBITDA 0.37 van
- Enphase nak Net debt/EBITDA 0.38 van
- Global Technologies nak Net debt/EBITDA 0.38 van
- RoodMicrotec N.V nak Net debt/EBITDA 0.38 van
- VentriPoint Diagnostics nak Net debt/EBITDA 0.38 van
- AM Resources nak Net debt/EBITDA 0.38 van
- Navidea Biopharmaceuticals Inc nak Net debt/EBITDA 0.38 van
- Caledonia Investments Plc nak Net debt/EBITDA 0.38 van
- Tymlez nak Net debt/EBITDA 0.38 van
- Synovus nak Net debt/EBITDA 0.39 van
- Eskay Mining nak Net debt/EBITDA 0.39 van
- Foxconn Interconnect Technology nak Net debt/EBITDA 0.39 van
- DermTech nak Net debt/EBITDA 0.39 van